Biotechnology - Biosimilars

Filter

Current filters:

Biosimilars

Popular Filters

1999 to 2023 of 2150 results

TNF inhibitors used for rheumatoid arthritis associated with increased skin cancer risk

08-09-2011

Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of…

Anti-Arthritics/RheumaticsBiotechnologyPharmaceuticalResearch

Global pharmacovigilance spending forecast to reach $15.46 billion by 2015

08-09-2011

Spending on pharmacovigilance will reach a value of $15.46 billion by 2015, compared with just under…

BiotechnologyFinancialGlobalPharmaceuticalRegulation

Germany dedicates billions to fund health care research

07-09-2011

Germany has allocated over 5.5 billion euros (nearly $8 billion) in federal grants to support health…

BiotechnologyEuropeFinancialPharmaceuticalResearch

Biogen Idec takes full control of Dompe JVs

07-09-2011

US biotech firm Biogen Idec (Nasdaq: BIIB) says it will acquire 100% of Milan, Italy-headquartered Dompe…

Biogen IdecBiotechnologyDompeMarkets & MarketingNeurological

NIH scientists repurpose Genzyme’s FDA-approved plerixafor for rare disease

05-09-2011

A new study reports that a drug already approved by the US Food and Drug Administration for use in patients…

BiotechnologyGenzymeImmunologicalsMozobilPharmaceuticalPlerixaforRare diseasesResearchSanofi

US pharma and FDA near agreement on PDUFA reauthorization, with 6% hike in user fees

05-09-2011

After many months of negotiations with the Food and Drug Administration, the USA’s pharmaceutical…

BiotechnologyFinancialNorth AmericaPharmaceuticalRegulation

EFPIA supports full transparency of clinical data, but with reservations

05-09-2011

The European Medicines Agency has carried out a consultation on increased transparency and access to…

BiotechnologyEuropePharmaceuticalRegulationResearch

Volatile markets in August take a toll on US life sciences IPOs, says Burrill

04-09-2011

Market volatility in August battered life sciences companies that went public this year, wiping away…

BiotechnologyDendreonFinancialPharmaceuticalProvenge

Japan’s Toyobo to increase capacity for injectables, eyeing biosimilars

04-09-2011

Japanese conglomerate Toyobo (TYOO: 3101) has outlined plans for its biosciences segment, which includes…

Asia-PacificBiotechnologyFinancialMarkets & MarketingPharmaceuticalToyobo

OXiGENE says Zybrestat Ph III study not feasible; cuts workforce as part of restructuring

01-09-2011

California, USA biotech OXiGENE (Nasdaq: OXGN), a clinical-stage, company developing novel therapeutics…

BiotechnologyFinancialOncologyOphthalmicsResearchZybrestat

PCMA outlines $100 billion in Rx drug savings in USA

01-09-2011

As the USA’s Joint Select Committee on Deficit Reduction examines options to reduce the deficit…

BiotechnologyGenericsHealthcareNorth AmericaPharmaceuticalPricingRegulation

Strong first-half 2011 for Vivalis, with net loss nearly halved

01-09-2011

French biotech firm Vivalis (Euronext Paris: VLS) has released its audited consolidated results for the…

BiotechnologyFinancialVivalis

US and European physicians wary of using biosimilars without clinical data backing

30-08-2011

The majority of US and European physicians are wary of using a biosimilar for an indication for which…

BiotechnologyEuropeGenericsMarkets & MarketingNorth AmericaResearch

New R&D tax credit to boost Australian research

26-08-2011

After more than two years of uncertainty over the fate of Australia’s new R&D Tax Credit, the relevant…

Asia-PacificBiotechnologyFinancialPharmaceuticalResearch

United Thera’s oral PAH drug treprostinil fails in Ph III study

26-08-2011

US biotech firm United Therapeutics (Nasdaq: UTHR) says that preliminary results from its FREEDOM-C(2)…

BiotechnologyRegulationResearchRespiratory and PulmonaryTreprostinilUnited Therapeutics

Shire drops Dermagraft for venous leg ulcers, after Ph III failure

25-08-2011

Ireland-headquartered drugmaker Shire (LSE: SHP) says that Advanced BioHealing (ABH), the USA-based regenerative…

Advanced BioHealingBiotechnologyDermagraftDermatologicalsPharmaceuticalRegulationResearchShire

CEL-SCI in deal to market Multikine in Argentina and Venezuela

24-08-2011

US drug developer CEL-SCI Corp (NYSE AMEX: CVM) has entered into an exclusive sales, marketing and distribution…

BiotechnologyCEL-SCI CorpIDC-GP PharmLicensingOncologyPharmaceuticalSouth America

GlaxoSmithKline gets 25% stake in spin-out firm Autifony

23-08-2011

UK pharma giant GlaxoSmithKline (LSE: GSK) has invested £1.25 million ($2.1 million) to receive a…

Autifony TherapeuticsBiotechnologyFinancialGlaxoSmithKlineMergers & Acquisitions

Orphan drug exclusion from US drug tax stand to harm innovation on rare diseases

22-08-2011

The US Internal Revenue Services' issuance of temporary and proposed regulations implementing the annual…

BiotechnologyFinancialNorth AmericaPharmaceuticalRare diseases

1999 to 2023 of 2150 results

Back to top